At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 23, 2026 at 16:05 ET
Anika Therapeutics held its 2026 Annual Meeting on June 18, 2026. Stockholders approved an amendment to the 2017 Omnibus Incentive Plan (the 'Revised Seventh Amended Plan') increasing the share reserve by 350,000 shares to 6,110,000 shares, and an amendment to the 2021 Employee Stock Purchase Plan doubling its share reserve from 200,000 to 400,000 shares. Three incumbent directors (Fischetti, Henneman, Griffin) were re-elected. This is a routine post-meeting administrative filing reflecting shareholder approval of previously disclosed equity plan increases.
- Stockholders approved the Revised Seventh Amended Plan, increasing authorized shares under the 2017 Omnibus Incentive Plan from 5,760,000 to 6,110,000 (a 350,000-share increase).
- Stockholders approved the ESPP Amendment, doubling the share reserve under the 2021 Employee Stock Purchase Plan from 200,000 to 400,000 shares.
- All three director nominees (Gary P. Fischetti, John B. Henneman III, Stephen D. Griffin) were elected with strong majorities (For votes ranging from 8.8M to 9.3M, against 56K-537K).
- Proposal 4 (equity plan) passed with approximately 8.0M For vs 1.3M Against, with 1.8M broker non-votes, notable opposition but approved.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access